본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Journal of the European Academy of Dermatology and Venereology : JEADV v.31 no.2, 2017년, pp.294 - 303   SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis

Augustin, M. (Institute for Health Services Research in Dermatology and Nursing (IVDP), German Center for Health Services Research in Dermatology (CVderm), University Medical Center Hamburg‐Eppendorf (UKE), Hamburg, Germany ); Blome, C. (Department of Dermatology, Paul Sabatier University, Toulouse, France ); Paul, C. (Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain ); Puig, L. (University of Münster, Münster, Germany ); Luger, T. (Department of Dermatology, Ghent University Hospital, Ghent, Belgium ); Lambert, J. (University of Rome, Rome, Italy ); Chimenti, S. (Department of Dermatology, University of Verona, Verona, Italy ); Girolomoni, G. (Århus University, Århus, Denmark ); Kragballe, K. (Janssen Cilag NV, Beerse, Belgium ); Naessens, D. (Janssen‐Cilag BV, Tilburg, The Netherlands ); Bergmans, P. (Janssen Pharmaceutica NV, Moscow, Russia ); Smirnov, P. (St John's Institute of Dermatology, King's College, London, UK ); Barker, J. (Dermatologikum, Hamburg, Germany ); Reich, K. ( );
  • 초록  

    Abstract Background TRANSIT (NCT01059773) compared immediate and gradual transition from methotrexate to ustekinumab in psoriasis patients via multiple measures, including patient‐reported outcomes. Objective To evaluate patient perception of treatment benefits in TRANSIT. Methods A total of 489 psoriasis patients received ustekinumab, with immediate cessation of methotrexate (Arm 1) or 4 weeks’ overlap with decreasing methotrexate dose (Arm 2). Ustekinumab was administered at weeks 0, 4, 16, 28 and 40. Dermatology Life Quality Index (DLQI), EuroQol 5‐item (EQ‐5D), visual analogue scale (VAS) valuation technique and patient benefit index (PBI) were employed. Mean global PBI and sub‐scores were calculated from the sum of the benefit items weighted by their respective relevance at baseline. Patient‐relevant benefit was defined as PBI ≥1 (scale: 0 [no benefit] to 4 [maximum benefit]). Correlations of global PBI with Psoriasis Area and Severity Index (PASI) and DLQI were examined. Results Relationships between PBI and clinical data were evaluable in 340 patients. The most important treatment goals at baseline included: ‘be healed of all skin defects’, ‘have confidence in therapy’, ‘get better skin quickly’ and ‘regain control of the disease’. Benefit in PBI global score was achieved at week 4 by 93% of patients in Arm 1 and 91% in Arm 2. Global PBI scores increased in both Arms between weeks 4 and 52. Global PBI correlated weakly with PASI change from baseline (correlation coefficient range: −0.22 to −0.40), and moderately with DLQI (−0.29 to −0.54). Overall DLQI score was lower than baseline at all times; and the percentage of patients with an overall score of 0 or 1 increased with time. Correspondingly, EQ VAS scores increased with time. DLQI and EQ VAS results were similar between arms. Conclusions Regardless of the strategy for transitioning from methotrexate, ustekinumab was associated with rapid and sustained improvement in patient‐reported outcomes. PBI appears a suitable tool for assessing patient‐relevant treatment benefits in psoriasis patients.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기